title: Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
abstract: Induction of leukemia-specific immune responses is a promising treatment for acute myeloid leukemia. A 58-year-old woman received Wilms' tumor 1 (WT1) peptide- and keyhole limpet hemocyanin (KLH)-pulsed, donor-derived dendritic cell (DC) vaccination for AML relapse after allogeneic stem cell transplantation. The vaccination induced immune responses to the naive antigen KLH, whereas definitive immune responses to WT1 were not detected. Leukemia gradually progressed despite of vaccination. This study indicates that DC vaccination can induce an antigen-specific immune response in a patient after allogeneic stem cell transplantation, thus representing a viable strategy to induce antigen-specific immune responses in such patients.
authors: Department of Hematology and Oncology, Kyoto University Hospital, Kyoto, Japan.
authors: Toshio
authors: T
authors: Kitawaki
authors: Norimitsu
authors: N
authors: Kadowaki
authors: Tadakazu
authors: T
authors: Kondo
authors: Takayuki
authors: T
authors: Ishikawa
authors: Tatsuo
authors: T
authors: Ichinohe
authors: Satoshi
authors: S
authors: Teramukai
authors: Masanori
authors: M
authors: Fukushima
authors: Yasunari
authors: Y
authors: Kasai
authors: Taira
authors: T
authors: Maekawa
authors: Takashi
authors: T
authors: Uchiyama
mesh_terms: D000276:Adjuvants, Immunologic; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006433:Hemocyanins / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016233:Immunotherapy, Active; D015479:Leukemia, Myelomonocytic, Acute / Q000628:therapy*; D019520:Living Donors; D008875:Middle Aged; D010446:Peptide Fragments / Q000276:immunology*; D010750:Phosphoproteins / Q000276:immunology; D016879:Salvage Therapy; D035781:Siblings; D014184:Transplantation, Homologous; D014763:Viral Matrix Proteins / Q000276:immunology; D025721:WT1 Proteins / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D007166:Immunosuppressive Agents; D010446:Peptide Fragments; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; D025721:WT1 Proteins; C065418:cytomegalovirus matrix protein 65kDa; D003561:Cytarabine; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin; D003630:Daunorubicin